Also known as: vitamins
Moleculin said its MIRACLE Phase 2B/3 AML trial is nearing first unblinding, with blinded CRc above 40% and CR around 30%. The first 45-subject readout is expected before June 30, 2026.
NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.
The FDA approved AstraZeneca’s Saphnelo Pen for once-weekly self-administration in adults with systemic lupus erythematosus. Approval was based on Phase III TULIP-SC results showing reduced disease activity versus placebo.
Additional phase 2 data showed alixorexton sustained improvements in disease severity, cognition and fatigue in narcolepsy type 1 through weeks 12-13. The oral orexin 2 receptor agonist was generally well tolerated, with no serious treatment-emergent adverse events reported.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
Systematic review identifies shared molecular signatures in brain and blood for major depressive disorder, while separate study finds brain-enriched circRNA can predict SSRI treatment response.
A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.
With semaglutide and tirzepatide shortages resolved, the FDA is cracking down on compounded GLP-1 medications. Concerns emerge over 33 unique compounded formulations with limited safety data and nonstandard delivery methods.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07605260 |
Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure. |
COMPLETED | NA |
| NCT07604350 |
Edaravone Dexborneol for Post-Stroke Epilepsy |
NOT_YET_RECRUITING | PHASE3 |
| NCT07604324 |
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07604311 |
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy: a Randomized, Double-blinded, Placebo-Controlled Trial |
NOT_YET_RECRUITING | PHASE4 |
| NCT07602582 |
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). |
NOT_YET_RECRUITING | PHASE3 |
| NCT07602166 |
Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans |
NOT_YET_RECRUITING | PHASE2 |
| NCT07601698 |
Dexmedetomidine vs Propofol-lidocaine Mixture in Preventing the Post Operative Emergence Agitation Following Sevoflurane Anasthesia |
NOT_YET_RECRUITING | PHASE4 |
| NCT07601425 |
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07601113 |
PG2 Breast Cancer Evaluation in Adjuvant Medicine-Survival Study |
NOT_YET_RECRUITING | |
| NCT07600736 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric Participants With KCNT1-related Epilepsy |
RECRUITING | PHASE2 |
